arrow
I

Ibiayi Dagogo-Jack

Harvard Medical School
H指数:39
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial

YAP/TEAD抑制剂VT3989在实体瘤中的研究:一项1/2期临床试验

2025-10-190
PRE
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study

一线免疫治疗联合或不联合化疗与BRAF联合MEK抑制剂在BRAFV600E突变型转移性非小细胞肺癌中的比较(FRONT-BRAF):一项多中心、回顾性队列研究

2025-09-290
PRE
Immune Composition and Immunotherapy Outcomes of Mesothelioma with BAP1, CDKN2A, MTAP, and NF2 Alterations

间皮瘤中BAP1、CDKN2A、MTAP和NF2变异的免疫组成和免疫治疗效果

2025-06-250
PRE
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC—A Brief Report

更新了来自II期PHAROS研究的encorafenib联合binimetinib在BRAF V600E突变型转移性NSCLC患者中的疗效和安全性——简报

2025-06-040
OAAI
Brief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated Tumors
2025-01-010
PRE
An unusual case of pericardial mass

心包肿块的罕见病例

2024-11-120
PRE
First Clinical Results from A Phase 1 Trial of PRT3789, a First-in-Class Intravenous SMARCA2 Degrader, in Patients with Advanced Solid Tumors with a SMARCA4 Mutation
2024-10-010
PRE
Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial
2024-07-010
OA
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer
2024-02-150
OAAI